title: Safety and efficacy of single-agent docetaxel (Taxotere) administered weekly in non-small cell lung carcinoma patients in Korea: An observational study.
abstract: To investigate the efficacy, safety, and tolerability of weekly docetaxel treatment in advanced non-small cell lung cancer (NSCLC) patients in Korea.
  
  
  
  This prospective observational study included Korean advanced NSCLC patients with Eastern Cooperative Oncology Group performance status <2 who received weekly monotherapy of docetaxel at a dose determined by the physician. Efficacy measurements included tumor response rate, overall survival (OS), progression-free survival, and one-year survival rate. Safety was analyzed through recorded incidences of adverse events (AEs), serious adverse events (SAEs), deaths, and other related safety parameters, along with their toxicity grades.
  
  
  
  Of 274 patients analyzed, one patient achieved a complete response and 42 partial responses; thus, the overall response rate was 15.7%. The OS rate at baseline and at one-year follow-up was 38.3% and 33.8%, respectively. AEs were reported in 229 (83.6%) patients. The most frequently reported hematologic AE of grade ≥3 was a decrease in neutrophils, with 6.6% of the patients developing neutropenia. In non-hematologic AEs of grade ≥3, the most common were infection with unknown absolute neutrophil count and death not associated with Common Terminology Criteria for Adverse Events (CTCAE) (4.7% each). The most common SAE reported was death, not associated with CTCAE (7.3%).
  
  
  
  In Korean patients, the weekly regimen of docetaxel monotherapy was safe and efficacious against advanced NSCLC.
authors.affiliation: Division of Medical Oncology Department of Internal Medicine Yonsei Cancer Center Seoul Korea; Division of Medical Oncology Department of Internal Medicine CHA University Bundang Medical Center Seongnam Korea.
authors.forename: Sun Min
authors.initials: SM
authors.lastname: Lim
authors.affiliation: Hanyang University College of Medicine Division of Hematology-Oncology Department of Internal Medicine Seoul Korea.
authors.forename: Byeong Bae
authors.initials: BB
authors.lastname: Park
authors.affiliation: Samsung Medical Center Department of Hematology-Oncology Seoul Korea.
authors.forename: Keun-Chil
authors.initials: KC
authors.lastname: Park
authors.affiliation: St. Vincent Hospital Department of Oncology Gyeonggi-do Korea.
authors.forename: Hoon-Kyo
authors.initials: HK
authors.lastname: Kim
authors.affiliation: Seoul National University Bundang Hospital Gyeonggi-do Korea.
authors.forename: Jong Seok
authors.initials: JS
authors.lastname: Lee
authors.affiliation: Daegu Catholic University Hospital Daegu Korea.
authors.forename: Sung Hwa
authors.initials: SH
authors.lastname: Bae
authors.affiliation: Kangbuk Samsung Medical Center Seoul Korea.
authors.forename: Seung-Sei
authors.initials: SS
authors.lastname: Lee
authors.affiliation: The Catholic University of Korea Seoul St. Mary's Hospital Seoul Korea.
authors.forename: Jin-Hyoung
authors.initials: JH
authors.lastname: Kang
authors.affiliation: Samsung Medical Center Department of Hematology-Oncology Seoul Korea.
authors.forename: Se-Hoon
authors.initials: SH
authors.lastname: Park
authors.affiliation: Gyeongsang National University Hospital Gyeongsang National University School of Medicine Gyeongnam Korea.
authors.forename: Gyeong-Won
authors.initials: GW
authors.lastname: Lee
authors.affiliation: NHIC Ilsan Hospital Gyeonggi-do Korea.
authors.forename: Hyo-Rac
authors.initials: HR
authors.lastname: Lee
authors.affiliation: Korea University Guro Hospital Seoul Korea.
authors.forename: Jae Hong
authors.initials: JH
authors.lastname: Seo
authors.affiliation: NHIC Ilsan Hospital Gyeonggi-do Korea.
authors.forename: Yong Tae
authors.initials: YT
authors.lastname: Kim
authors.affiliation: Korea Cancer Center Hospital Seoul Korea.
authors.forename: Sung Hyun
authors.initials: SH
authors.lastname: Yang
authors.affiliation: Division of Medical Oncology Department of Internal Medicine Yonsei Cancer Center Seoul Korea.
authors.forename: Joo-Hang
authors.initials: JH
authors.lastname: Kim
keywords: Carcinoma; docetaxel; non‐small cell lung cancer; safety